|
Synonyms: RC18 | Tai'ai®
telitacicept is an approved drug (China (2021))
Compound class:
Peptide or derivative
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
|
| Immunopharmacology Comments |
| Telitacicept is approved in China as a treatment for active SLE. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Approved therapy for SLE | |
